Geniospasm

Geniospasm is a rare inherited movement disorder in which the mentalis muscle of the chin contracts in rhythmic bursts, producing visible trembling of the chin and lower lip while the rest of the neurological examination remains normal.

It is lifelong, usually begins in early childhood, is provoked by stress or emotion and is not epileptic, although the visible movements can be mistaken for a seizure by parents and by clinicians who have never seen the condition.

Terminology and classification

• Standard English names are geniospasm, hereditary geniospasm and chin tremor, and older British reports used the descriptive phrase hereditary quivering of the chin.^[1]
• The term geniospasm was coined to separate the chin movement from facial myokymia, hemifacial spasm and palatal tremor, which differ in anatomy, electromyographic pattern and treatment response.
• ICD-10 classifies it under G25.3, myoclonus, while the ICD-11 mortality and morbidity statistics have no dedicated category and Orphanet lists no ICD-11 mapping for the disorder.
• Other identifiers are OMIM 190100, Orphanet ORPHA:53372, MONDO:0008588, GARD 9501, UMLS C2931589, a supplementary MeSH concept and Wikidata Q3816650.
• It belongs to the paroxysmal movement disorders rather than to epilepsy, and the involuntary movement is confined to the mentalis muscle in almost every reported patient.
• Some authors treat late-onset and sporadic chin tremor as separate entities, but the familial form with childhood onset and a dominant pedigree is the core phenotype described in the literature.

History

• Laurance, Matthews and Diggle described hereditary quivering of the chin in 1968 in the Archives of Disease in Childhood, establishing the condition as a familial, non-epileptic phenomenon.^[1]
• Jarman and colleagues performed linkage analysis in 1997 in two unrelated British families and mapped one family to chromosome 9q13-q21 with a maximum two-point lod score of 5.24 at marker D9S1837.^[2]
• The same study found a second large family that was not linked to 9q13-q21, providing early evidence of genetic heterogeneity and implying that at least one additional locus remains unknown.
• A 1999 survey counted only 23 affected families worldwide, and later reviews showed that the literature consisted almost entirely of case reports and small pedigrees rather than population studies.
• Hull and Parnes reported in 2020 that regular onabotulinumtoxinA injections abolished bothersome chin movements in their patient and in nine previously published patients, shifting management towards a targeted local treatment.^[3]
• A 2022 systematic review assembled 489 published patients and provided the first quantitative description of onset, triggers, sleep involvement, complications and prognosis, and a 2025 practical review restated the benign but persistent nature of the disorder.^[1]

Epidemiology

• No population-based prevalence has been measured, and Orphanet records prevalence as unknown, so all frequency statements rest on published case counts and family surveys.
• The largest synthesis identified 489 patients in 41 articles, which almost certainly under-represents mild familial cases that never reach a neurologist.
• There is a slight male excess, with a male to female ratio of about 1.2 to 1 in the pooled series and 1.3 to 1 in the earlier Orphanet summary.
• A family history is present in 98.6 percent of reported patients, and 68.1 percent have onset before the age of one year, which reflects ascertainment of the dominantly inherited form.
• Emotional triggers are reported by 91.4 percent, sleep-related episodes by 25.7 percent and regular paroxysms at least weekly by 55.2 percent, whereas only 11.1 percent develop complications.
• The condition is described in Europe, North America, Asia and South America, and the few reports from consanguineous or isolated communities do not suggest a single founder effect.
• Because transmission is autosomal dominant with high penetrance, each child of an affected parent has a 50 percent chance of inheriting the trait, and this recurrence risk is the basis of genetic counselling for affected families.
• Ascertainment has expanded from 23 families known worldwide in 1999 to 489 published patients by 2022, which indicates that earlier frequency statements reflected limited case finding rather than a true change in occurrence.

Pathophysiology

• The visible movement is produced by repetitive discharges of the mentalis muscle, a paired midline muscle that elevates and wrinkles the skin of the chin and everts the lower lip.
• Surface electromyography shows rhythmic bursts at about 8 Hz superimposed on a slower, higher-amplitude oscillation of roughly one cycle every three seconds, which gives the characteristic fluttering appearance.
• The clinical and electromyographic pattern resembles brainstem myoclonus, and the disorder is therefore classified as a segmental myoclonus rather than as tremor or dystonia.
• The responsible gene has not been identified, and the 9q13-q21 interval contains many genes but no confirmed pathogenic variant has been reported in multiple families.
• Penetrance is high in linked pedigrees, and transmission is autosomal dominant, although sporadic cases and families without linkage suggest additional genetic or environmental mechanisms.
• The movements persist during sleep in a quarter of patients, which argues against a purely voluntary or attention-dependent mechanism and supports an intrinsic brainstem oscillator.

Clinical features

• The hallmark is episodic involuntary up-and-down movement of the chin and lower lip, often described by families as a quiver, flutter or tremble that appears in infancy or early childhood.
• Episodes last seconds to minutes, may cluster many times per day and are consistently worsened by stress, concentration, embarrassment, fatigue and emotional conversation.
• Most patients have an otherwise normal neurological examination, normal intelligence and normal speech, and the chin movement is the only neurological finding in affected families.
• Bothersome complications are uncommon but include tongue biting, difficulty drinking, self-consciousness, social anxiety and avoidance of photographs or public speaking.
• The tremor may spread to adjacent facial muscles, the tongue or the floor of the mouth in a minority, and a few patients report sleep disturbance or nocturnal episodes.
• Complete remission is rare and occurred in only 9.9 percent of pooled cases, although the amplitude and frequency usually decline gradually through adolescence and adult life.

Diagnosis

• Diagnosis is clinical and rests on the characteristic chin movement, a positive family history in most cases, a normal neurological examination and the absence of epileptic features.
• Video recording of an episode and surface electromyography of the mentalis muscle are the most useful confirmatory tests and demonstrate the characteristic 8 Hz bursting pattern.
• Electroencephalography is normal during episodes, which helps to exclude epileptic myoclonus, and brain magnetic resonance imaging is usually normal and is performed to exclude structural brainstem disease.
• Genetic testing cannot confirm the diagnosis because no gene is known, and testing of the 9q13-q21 region is confined to research settings.
• The differential diagnosis includes essential tremor, palatal tremor, hemifacial spasm, facial myokymia, oromandibular dystonia, tics, epilepsia partialis continua and functional movement disorder.
• Red flags that should prompt imaging or further testing include adult onset, progressive spread, weakness, sensory loss, cranial nerve deficits, abnormal electroencephalography and a negative family history with sudden onset.

Management

• Most patients need only explanation and reassurance, because the disorder is benign, non-progressive and does not impair intelligence, swallowing or facial expression.
• Regular botulinum toxin injections into the mentalis muscle are the treatment of choice for bothersome symptoms, and published experience with onabotulinumtoxinA reports complete or near-complete relief without impairing speech or facial expression.^[4]
• Injection is guided by palpation or electromyography, is repeated every three to four months and requires counselling about transient bruising, asymmetry and rare weakness of the lower lip.
• Oral pharmacological options such as clonazepam, levetiracetam, propranolol and trihexyphenidyl have been tried with inconsistent or absent benefit and are not recommended as routine therapy.
• General measures include sleep hygiene, stress management, relaxation training, avoidance of excessive caffeine and psychological support for patients whose social functioning is affected.
• Follow-up should document episode frequency, interference with eating or speaking and treatment response, and pregnancy or breastfeeding requires individual discussion because botulinum toxin data are limited.
• Referral to speech-language pathology is appropriate when tongue biting or articulation difficulties interfere with eating or speaking, and cognitive behavioural therapy can treat the social anxiety that leads patients to avoid photographs and public speaking.
• Patients who decline botulinum toxin can be managed with watchful waiting, trigger avoidance and annual review, because the disorder is non-progressive and does not shorten life expectancy.

Research and controversies

• The identity of the geniospasm gene remains the central unresolved question, and modern sequencing in linked families has not produced a replicated candidate.
• Whether sporadic adult-onset chin tremor is the same disease as familial childhood geniospasm is debated, because the sporadic form lacks linkage data and may have heterogeneous causes.
• Botulinum toxin is widely used but has never been tested in a randomized controlled trial, and optimal dose, injection interval and target muscles are based on case series only.
• Outcome measurement is hampered by the lack of a validated severity scale, and future trials will need video-based or electromyographic endpoints that capture paroxysm frequency and amplitude.
• Patient registries and international collaboration are needed because individual centres see only a handful of families, and natural history beyond middle age is almost unknown.
• Functional and structural imaging studies have so far been unrevealing, and whether the brainstem oscillator is a target for deep brain stimulation or other neuromodulation remains entirely speculative.